Abstract
Small molecule aggregators non-specifically inhibit multiple unrelated proteins, rendering them therapeutically useless. They frequently appear as false hits and thus need to be eliminated in high-throughput screening campaigns. Computational methods have been explored for identifying aggregators, which have not been tested in screening large compound libraries. We used 1319 aggregators and 128,325 non-aggregators to develop a support vector machines (SVM) aggregator identification model, which was tested by four methods. The first is five fold cross-validation, which showed comparable aggregator and significantly improved non-aggregator identification rates against earlier studies. The second is the independent test of .17 aggregators discovered independently from the training aggregators, 71% of which were correctly identified. The third is retrospective screening of 13M PUBCHEM and 168K MDDR. compounds, which predicted 97.9% and 98.7% of the PUBCHEM and MDDR compounds as non-aggregators. The fourth is retrospective screening of 5527 MDDR compounds similar to the known aggregators, 1,14% of which were predicted as aggregators. SVM showed slightly better overall performance against two other machine learning methods based on five fold cross-validation studies of the same settings. Molecular features of aggregation, extracted by a feature selection method, are consistent with published profiles. SVM showed substantial capability in identifying aggregators from large libraries at low false-hit rates.
Original language | English (US) |
---|---|
Pages (from-to) | 752-763 |
Number of pages | 12 |
Journal | Journal of Computational Chemistry |
Volume | 31 |
Issue number | 4 |
DOIs | |
State | Published - Mar 2010 |
Keywords
- Active compound
- Aggregation
- Aggregator
- Drug discovery
- High throughput screening
- Machine learning method
- Recursive feature elimination
- Support vector machine
- Virtual screening
ASJC Scopus subject areas
- Chemistry(all)
- Computational Mathematics